Literature DB >> 20390435

Treatment of Wernicke's encephalopathy with high dose of thiamine in a patient with pyloric sub-stenosis: description of a case.

Francesca Caso1, A Fiorino, M Falautano, L Leocani, V Martinelli, F Minicucci, A Falini, G Comi, G Magnani.   

Abstract

Wernicke's encephalopathy (WE) is an acute or subacute syndrome that results from a deficiency in vitamin B1 (thiamine). The syndrome is characterised by a classical triad of symptoms: nystagmus and ophthalmoplegia,mental-status changes, and unsteadiness of stance and gait. When patients with WE are inappropriately treated with low doses of thiamine, mortality rates average out at 20% and Korsakoff's Psychosis develops in about 85% of survivors(Sechi and Serra in Lancet Neurol 6(5):442–455,2007). We report the case of a patient with a pyloric substenosis that developed a WE, and was treated with high doses of thiamine showing after few days of treatment a great improvement of neurological and neuroradiological assessment, even though cognitive impairment was still severe at discharge and at 6 months follow-up.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20390435     DOI: 10.1007/s10072-010-0253-1

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  9 in total

1.  Wernicke encephalopathy: MR findings at clinical presentation in twenty-six alcoholic and nonalcoholic patients.

Authors:  G Zuccoli; M Gallucci; J Capellades; L Regnicolo; B Tumiati; T Cabada Giadás; W Bottari; J Mandrioli; M Bertolini
Journal:  AJNR Am J Neuroradiol       Date:  2007-08       Impact factor: 3.825

Review 2.  Mechanisms of vitamin deficiency in chronic alcohol misusers and the development of the Wernicke-Korsakoff syndrome.

Authors:  A D Thomson
Journal:  Alcohol Alcohol Suppl       Date:  2000 May-Jun

3.  Prevention and treatment of Wernicke-Korsakoff syndrome.

Authors:  C C Cook
Journal:  Alcohol Alcohol Suppl       Date:  2000 May-Jun

Review 4.  Wernicke's encephalopathy: new clinical settings and recent advances in diagnosis and management.

Authors:  Gianpietro Sechi; Alessandro Serra
Journal:  Lancet Neurol       Date:  2007-05       Impact factor: 44.182

5.  The treatment of patients at risk of developing Wernicke's encephalopathy in the community.

Authors:  Allan D Thomson; E Jane Marshall
Journal:  Alcohol Alcohol       Date:  2005-12-29       Impact factor: 2.826

Review 6.  Paraneoplastic neurological syndromes: an update on diagnosis, pathogenesis, and therapy.

Authors:  Raymond Voltz
Journal:  Lancet Neurol       Date:  2002-09       Impact factor: 44.182

Review 7.  Thiamine for Wernicke-Korsakoff Syndrome in people at risk from alcohol abuse.

Authors:  E Day; P Bentham; R Callaghan; T Kuruvilla; S George
Journal:  Cochrane Database Syst Rev       Date:  2004

8.  Temporal consciousness and confabulation: is the medial temporal lobe "temporal"?

Authors:  Gianfranco Dalla Barba; Marie-Francoise Boisse
Journal:  Cogn Neuropsychiatry       Date:  2010-01       Impact factor: 1.871

Review 9.  Neuroimaging findings in acute Wernicke's encephalopathy: review of the literature.

Authors:  Giulio Zuccoli; Nicolò Pipitone
Journal:  AJR Am J Roentgenol       Date:  2009-02       Impact factor: 3.959

  9 in total
  3 in total

1.  Wernicke's encephalopathy in a child with high dose thiamine therapy.

Authors:  So Won Park; Yoon Young Yi; Jung Woo Han; Heung Dong Kim; Joon Soo Lee; Hoon-Chul Kang
Journal:  Korean J Pediatr       Date:  2014-11-30

2.  Wernicke's Encephalopathy due to Non-Alcoholic Gastrointestinal Tract Disease.

Authors:  İpek Güngör Doğan; Güneş Uzun Altiokka; Fulya Türker; Bülent Saka; Başar Bilgiç; Elif Kocasoy Orhan
Journal:  Noro Psikiyatr Ars       Date:  2018-04-25       Impact factor: 1.339

3.  Thiamine Prescribing Practices for Adult Patients Admitted to an Internal Medicine Service.

Authors:  Uzma Alim; Duane Bates; Ashten Langevin; Denise Werry; Deonne Dersch-Mills; Robert J Herman; Marcy Mintz; Sunita Ghosh
Journal:  Can J Hosp Pharm       Date:  2017-06-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.